Skip to main content

Table 1 Demographic characteristics at the time of transplantation

From: Effect of induction therapy on the expression of molecular markers associated with rejection and tolerance

Variable

No-induction

rATG

Basiliximab

P value

Number

19

24

17

 

Gender (M/F)

9/10

16/8

9/8

ns†

Recipient age (years)*

57 [27; 70]

54 [21; 78]

53 [25; 65]

ns‡

Donor age (years)*

52 [16; 68]

46 [18; 74]

61 [21; 75]

<0.05‡a

HLA MM*

3 [2; 6]

3 [1; 5]

3 [2; 5]

ns‡

1st/2nd and 3rd KTx (n)

19/0

11/13§

16/1

<0.0001†

PRA (%)*

4 [0; 22]

68 [0; 96]

6 [2; 63]

<0.0001‡b

CNI (TAC/CsA) (n)

21/4

28/0

18/0

ns†

CIT (hours)*

16.2 [11.0; 20.7]

15.4 [7.7; 20.1]

17.2 [7.7; 21.0]

ns‡

Dialysis time (years)*

2.0 [0.2; 5.7]

1.9 [0.5; 6.4]

2.0 [0.6; 4.9]

ns‡

Cause of renal failure

   

ns†

 Primary GN

9

9

4

 

 Hereditary diseases

2

5

4

 

 Diabetic or ischemic nephropathy

6

2

7

 

 TIN

2

1

1

 

 ANCA vasculitis or lupus nephritis

0

4

0

 

 Other causes

0

3

1

 
  1. ANCA Anti-neutrophil cytoplasmic antibodies, CIT cold ischemic time, CNI calcineurin inhibitor, CsA cyclosporine A, GN glomerulonephritis, HLA MM HLA mismatch, PRA historical panel-reactive antibodies, measured every 3 months before transplantation (the highest number in each patient was considered), TAC tacrolimus, TIN tubulointerstitial nephritis, TxR renal transplantation
  2. *Median [min; max]; †Chi square test P value; ‡Kruskal-Wallis test P value
  3. Dunn's Multiple Comparison Test: aSignificant difference between the basiliximab group and the rATG group and a bsignificant difference between rATG and the no-induction or basiliximab group
  4. §2 patients had a 3rd transplantation